Journal article
A preliminary analysis of interleukin-1 ligands as potential predictive biomarkers of response to cetuximab
Biomarker research, Vol.7(1), pp.14-14
07/16/2019
DOI: 10.1186/s40364-019-0164-0
PMCID: PMC6636109
PMID: 31346466
Abstract
Background: The epidermal growth factor receptor (EGFR) monoclonal IgG1 antibody cetuximab is approved for first-line treatment of recurrent and metastatic (R/M) HNSCC as a part of the standard of care EXTREME regimen (platinum/5-fluorouracil/cetuximab). This regimen has relatively high response and disease control rates but is generally not curative and many patients will experience recurrent disease and/or metastasis. Therefore, there is a great need to identify predictive biomarkers for recurrence and disease progression in cetuximab-treated HNSCC patients to facilitate patient management and allow for treatment modification. The goal of this work is to assess the potential of activating interleukin-1 (IL-1) ligands (IL-1 alpha [IL-1α], IL-1 beta [IL-1β]) as predictive biomarkers of survival outcomes in HNSCC patients treated with cetuximab-based chemotherapy.
Methods: Baseline gene, serum and tumor expression of interleukin-1 (IL-1) ligands were analyzed from The Cancer Genome Atlas (TCGA) database or clinical trials of cetuximab-based therapies and interrogated for associations with clinical outcome data.
Results: High tumor gene expression of IL-1β was associated with a more favorable overall survival in cetuximab-treated HNSCC patients but not in non-cetuximab-treated patients. In HNSCC patients treated with cetuximab-based chemotherapy, higher gene and circulating levels of IL-1α and IL-1β were correlated with a more favorable progression free survival compared to patients with low or undetectable levels of IL-1 ligands.
Conclusions: These findings suggest that IL-1 ligands may function as predictive biomarkers for tumor response to cetuximab-based chemotherapy in HNSCC patients and warrants further investigation and validation in larger clinical studies.
Keywords: Biomarker; Cetuximab; Head and neck squamous cell carcinoma (HNSCC); Interleukin-1 (IL-1).
Details
- Title: Subtitle
- A preliminary analysis of interleukin-1 ligands as potential predictive biomarkers of response to cetuximab
- Creators
- Madelyn Espinosa-Cotton - Iowa City, IA USAElana J Fertig - Johns Hopkins UniversityLaura P Stabile - University of PittsburghAutumn Gaither-Davis - Pittsburgh, PA USAJulie E Bauman - University of ArizonaSandra Schmitz - UCLouvainKatherine N Gibson-Corley - Iowa City, IA 52242 USAYinwen Cheng - University of IowaIsaac J Jensen - University of IowaVladimir P Badovinac - University of IowaDouglas Laux - University of Iowa Hospitals and ClinicsAndrean L Simons - University of Iowa
- Resource Type
- Journal article
- Publication Details
- Biomarker research, Vol.7(1), pp.14-14
- DOI
- 10.1186/s40364-019-0164-0
- PMID
- 31346466
- PMCID
- PMC6636109
- NLM abbreviation
- Biomark Res
- ISSN
- 2050-7771
- eISSN
- 2050-7771
- Publisher
- BioMed Central
- Grant note
- R01DE024550; P50DE019032 / ; T32AI007511 / ; F99CA223062; R01CA177669; P30CA006973 / ; 16-80-44-SIMO / ;
- Language
- English
- Date published
- 07/16/2019
- Academic Unit
- Oral Pathology, Radiology and Medicine; Microbiology and Immunology; Hematology, Oncology, and Blood & Marrow Transplantation; The University of Iowa Institute for Vision Research; Pathology; Pharmaceutical Sciences and Experimental Therapeutics; Radiation Oncology; Internal Medicine; Ophthalmology and Visual Sciences
- Record Identifier
- 9984181071002771
Metrics
34 Record Views